A119 NeVa ONE registry: recanalization outcomes by lesion location in a real-world patient cohort

<h3>Introduction</h3> Recanalization rates are typically lower in ICA occlusions, with first-pass mTICI 2b-3 rates ranging from 30% to 50% due thrombus length and anatomical complexity. The NeVa stent retriever has demonstrated high recanalization effectiveness with a favorable safety profile in mechanical thrombectomy of LVOs. <h3>Aim of Study</h3> NeVa ONE is a multicenter, international, prospective registry designed to assess outcomes in a real-world patient cohort. This interim analysis descriptively compares different lesion locations and corresponding recanalization outcomes. <h3>Method</h3> This analysis includes 350 patients treated using NeVa as a first-line approach. Outcomes are assessed across occlusions in the ICA, MCA (M1, M2), and BA. Endpoints include successful (TICI2b-3) and complete (TICI 2c-3) recanalization achieved at first pass (mFPE/FPE) and at procedure end. Secondary endpoints include device/procedure-related adverse events. <h3>Results</h3> Occlusion sites were: ICA (28.0%), M1 (57.1%), M2 (10.9%) and BA (4%). Baseline characteristics were comparable across lesion locations with slight deviations for the smaller-sized basilar artery group: Age 67–72 years, NIHSS 13–16, ASPECTS 8–10. Common comorbidities included hypertension (68–75%), dyslipidemia (43–50%), diabetes (20–33%), and atrial fibrillation (25–43%). mFPE rates were 66.7% (ICA), 77% (MCA M1), 81.6% (MCA M2), and 71.4% (BA). Corresponding FPE rates were 53.5%, 65%, 52.6%, and 50%. <h3>Conclusion</h3> The NeVa ONE Registry reflects real-world outcomes for LVO AIS patients treated with NeVa. Recanalization rates for ICA occlusions were comparable to other lesion locations, highlighting NeVa’s consistent performance across complex territories. <h3>Conflict of Interest</h3> No